Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zevra Therapeutics ( (ZVRA) ) has issued an announcement.
On December 11, 2025, Zevra Therapeutics announced organizational changes in its financial leadership. Timothy Sangiovanni, the current Senior Vice President, Finance and Corporate Controller, was appointed interim principal financial officer effective January 1, 2026, reflecting his extensive experience in financial reporting and corporate control within the company since 2015. The appointment did not alter his compensation arrangements.
The most recent analyst rating on (ZVRA) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Zevra Therapeutics stock, see the ZVRA Stock Forecast page.
Spark’s Take on ZVRA Stock
According to Spark, TipRanks’ AI Analyst, ZVRA is a Neutral.
Zevra Therapeutics’ overall score is driven by strong revenue growth and reasonable valuation, offset by significant challenges in profitability and cash flow management. Technical indicators suggest a bearish trend, but the company’s strategic initiatives and robust financial position provide a foundation for future growth.
To see Spark’s full report on ZVRA stock, click here.
More about Zevra Therapeutics
Average Trading Volume: 1,805,847
Technical Sentiment Signal: Sell
Current Market Cap: $457.1M
Find detailed analytics on ZVRA stock on TipRanks’ Stock Analysis page.